External Links
This page houses links to various sites and resources related to Drug Discovery that exist outside of the University of Rochester.
Academic Partners
Moulder Center for Drug Discovery Research
The Center's research team is involved in multidisplinary research. Recent publications reflect the center's research interest in multiple diseases at various stages of drug discovery. The center's research capabilities are enhanced through collaborations and partnerships.
Potential Corporate Partners
Eli Lilly PD2 Program
This program is a phenotypic drug discovery process designed to identify compounds that modulate cellular processes by screening novel molecules in disease-relevant assays.
PD2 at a glance:
- Lilly will provide no-cost access to phenotypic assay panel for external investigators.
- PD2 panel includes disease-relevant assays.
- Confidential compound submission via web-based interface.
- Full data report provided to investigator.
- Promising findings can serve as basis for a collaboration agreement
Johnson and Johnson’s COSAT Program
The Corporate Office of Science and Technology (COSAT) was created in 1978 to foster J&J’s long-standing focus on innovation and entrepreneurship. It was formed by assembling a team of senior scientists and clinicians whose primary objective is to identify, nurture, and guide emerging technologies and products.
Drug Discovery Information Sites
Drug Discovery Portal (Strathclyde, UK)
The focus of the Drug Discovery Portal is matching academic chemists and academic biologists through intelligent virtual screening performed by experienced researchers.
Services provided by the Drug Discovery Portal are:
- Hit identification
- Hit-to-lead optimization (computational support and/or synthetic medicinal chemistry output)
- Library analysis and design
- Allosteric site identification
Screening & Chemical Biology Links
Eli Lilly PD2 Program
This program is a phenotypic drug discovery process designed to identify compounds that modulate cellular processes by screening novel molecules in disease-relevant assays.
PD2 at a glance:
- Lilly will provide no-cost access to phenotypic assay panel for external investigators.
- PD2 panel includes disease-relevant assays.
- Confidential compound submission via web-based interface.
- Full data report provided to investigator.
- Promising findings can serve as basis for a collaboration agreement.
NIH Common Fund - Molecular Libraries and Imaging Overview
Overview of molecular libraries program in context of NIH roadmap including funding opportunities.
Molecular Libraries Program
Introduction to resources available through molecular probe centers.
Molecular Libraries Program - Probe Production Centers
List of NIH screening centers, contacts, and capabilities.
PubChem
A public repository for chemical structures and their biological properties.
NIH Chemical Genomics Center
The center provides access to a wide variety of resources related to screening. There screening guidance manual is very useful for investigators new to screening.
Institute for Chemistry and Chemical Biology at Harvard Medical School
Very useful site for general screening and also will allow non-Harvard screeners.
Center for Chemical Genomics at University of Michigan Life Sciences Institute
Comprehensive screening center that will collaborate with outside investigators to do large scale screening.
NIH Drug Development Projects
NIH Rapid Access to Interventional Development (NIH-RAID)
Rapid Access to Interventional Development: (RAID) provides funds to support early stage development of candidate molecules including compound productions, PK/PD, and toxicology studies. Competitive grant process but does not provide salary support for investigators.
NIH Bench-to-Bedside Awards Program
These two-year awards designed to seed new projects that propose to translate basic science to human subjects. Proposals can fall into one of seven categories: pharmacogenomics, behavioral and social sciences, rare diseases, AIDS, minority health and health disparities, women’s health, and general projects. A letter of intent must be submitted by Wednesday, September 22, 2010.
Gates Grand Challenges
Provides support for very specific types of projects.
Contract Synthesis Companies
Meetings & Conferences
Specific Meetings
Conference Series with Drug Discovery Topics
Sites Listing Drug Discovery Meetings
